Creatine phosphokinase elevation exacerbated by levetiracetam therapy

A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levet...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Julia E., Choe, Dongwhoon J., Doherty, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308055/
https://www.ncbi.nlm.nih.gov/pubmed/25667904
http://dx.doi.org/10.1016/j.ebcr.2014.09.008
_version_ 1782354540409913344
author Isaacson, Julia E.
Choe, Dongwhoon J.
Doherty, Michael J.
author_facet Isaacson, Julia E.
Choe, Dongwhoon J.
Doherty, Michael J.
author_sort Isaacson, Julia E.
collection PubMed
description A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive seizure.
format Online
Article
Text
id pubmed-4308055
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-43080552015-02-09 Creatine phosphokinase elevation exacerbated by levetiracetam therapy Isaacson, Julia E. Choe, Dongwhoon J. Doherty, Michael J. Epilepsy Behav Case Rep Case Report A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive seizure. Elsevier 2014-10-22 /pmc/articles/PMC4308055/ /pubmed/25667904 http://dx.doi.org/10.1016/j.ebcr.2014.09.008 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Case Report
Isaacson, Julia E.
Choe, Dongwhoon J.
Doherty, Michael J.
Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_full Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_fullStr Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_full_unstemmed Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_short Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_sort creatine phosphokinase elevation exacerbated by levetiracetam therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308055/
https://www.ncbi.nlm.nih.gov/pubmed/25667904
http://dx.doi.org/10.1016/j.ebcr.2014.09.008
work_keys_str_mv AT isaacsonjuliae creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy
AT choedongwhoonj creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy
AT dohertymichaelj creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy

Ejemplares similares